Stoke Therapeutics (STOK) Faces A Valuation Test Following Weaker Nine Month Results
Stoke Therapeutics to Present at Upcoming Investor Conferences in November
Stoke Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation
Stoke Therapeutics (STOK) Stock Price Faces Q3 Results Cash Burn Question
Stoke (STOK) Q3 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. Q3 2026 Earnings Call Summary
Stoke Therapeutics Q3 Earnings Call Highlights
Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
Stoke Therapeutics Q3 2026 Earnings Call Transcript
Stoke Therapeutics Q3 EPS $(1.08) Misses $(0.93) Estimate, Sales $11.255M Beat $8.185M Estimate
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
Stoke Therapeutics: The Market Misread A Key FDA Win
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Stoke Therapeutics Presents Data For STK-002 Supporting Disease-Modifying Potential In Autosomal Dominant Optic Atrophy At AAO 2026 Annual Meeting
FDA Alignment on Zorevunersen Endpoints Could Be A Game Changer For Stoke Therapeutics (STOK)
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.